ChromaDex Appoints Yan Chu as Managing Director, Asia Pacific
October 02 2018 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed
Yan Chu as Managing Director, Asia Pacific, effective today. Based
in Singapore, Chu will lead the TRU NIAGEN® business for the
region.
Chu is joining ChromaDex from Comvita, an international health
products company, where she served as Regional General Manager
overseeing the Hong Kong, Japan, and Korea markets. Previously, Chu
led sales and marketing functions in the Asia Pacific region at
Crocs, Adidas, and The Body Shop.
With a career in growing retail brands throughout Asia Pacific
markets, Yan has extensive experience in brand marketing, channel
development, and product development.
“We are thrilled to welcome Yan to the company,” says ChromaDex
CEO Rob Fried. “Her impressive experience and strong business
judgment will be important to the expansion of TRU NIAGEN® in the
Asia Pacific region.”
“I am very excited to be a part of the ChromaDex team,” says
Chu. “Asia Pacific is a region with immense opportunity, and I look
forward to contributing to the presence and growth of TRU NIAGEN®
in all strategic markets.”
Chu holds a Bachelor of Commerce and a Bachelor of Science
degree from Deakin University in Australia.
For additional information on the science supporting TRU NIAGEN
visit www.truniagen.com.
About ChromaDex:ChromaDex Corp. is an
integrated, global nutraceutical company devoted to improving the
way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
About TRU NIAGEN®:TRU NIAGEN® is a branded
dietary supplement brought to market by key nicotinamide riboside
innovator and patent holder, ChromaDex. NIAGEN® nicotinamide
riboside (NR), also supplied by ChromaDex, is the sole active
ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate
NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide)
levels, which decline with age. Only NIAGEN® has twice been
successfully reviewed under FDA's new dietary ingredient (“NDI”)
notification program, and has also been successfully notified to
the FDA as generally recognized as safe (“GRAS”).
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 30, 2017, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof. ChromaDex
provided research materials and a portion of the grant funding as a
collaborator for the study.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships(949) 648-3775alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Sr. Director of FP&A and Investor Relations(949)
600-9727briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024